Experts and Doctors on protein kinase inhibitors in Kitakyushu, Fukuoka, Japan


Locale: Kitakyushu, Fukuoka, Japan
Topic: protein kinase inhibitors

Top Publications

  1. Uramoto H, Uchiumi T, Izumi H, Kohno K, Oyama T, Sugio K, et al. A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR. Anticancer Res. 2007;27:2297-303 pubmed
    ..This study suggests that screening tumour samples for a range of EGFR mutations may improve our ability to identify the patients most likely to benefit from EFGR TKIs. ..
  2. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res. 2009;46:572-80 pubmed publisher
    ..Our findings indicate that AGEs induce calcification of vascular smooth muscle cells by osteoblast-like differentiation of smooth muscle cells through RAGE/p38 MAPK. ..
  3. Nose N, Uramoto H, Iwata T, Hanagiri T, Yasumoto K. Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer. 2011;71:350-5 pubmed publisher
    ..Further investigation will be necessary to identify biomarkers using a larger cohort of patients in a prospective study. ..
  4. Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol. 2013;23:415-24 pubmed publisher
    ..Taken together, an orally available kinase inhibitor tofacitinib targeting JAK-mediated signals would be expected to be a new option for RA treatment. ..
  5. Wang S, Iwata S, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 2014;73:2213-5 pubmed publisher
  6. Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34 pubmed publisher
    ..The risk of herpes zoster appears to be higher in Japanese patients treated with tofacitinib than in the global population. NCT00661661 . Registered 7 February 2008. ..
  7. Tanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J Intern Med. 2016;31:210-8 pubmed publisher
    ..Contrarily, for established RA, fewer patients sustained remission after the discontinuation of biological DMARD and "deep remission" at the discontinuation was a key factor to keep the treatment holiday of biological DMARD. ..